Successful Management with Vincristine after Failure of Prednisolone Therapy for Diffuse Neonatal Hemangiomatosis.
- Author:
Hak Sung LEE
1
;
Soon Young HEO
;
Won Duck KIM
Author Information
1. Department of Pediatrics, Daegu Fatima Hospital, Daegu, Korea. neogubugi@yahoo.co.kr
- Publication Type:Case Report
- Keywords:
Diffuse neonatal hemangiomatosis;
Vincristine
- MeSH:
Adrenal Cortex Hormones;
Cerebral Palsy;
Fatal Outcome;
Hemangioma;
Humans;
Infant, Newborn;
Interferons;
Kasabach-Merritt Syndrome;
Prednisolone*;
Radiotherapy;
Thrombocytopenia;
Vincristine*
- From:Korean Journal of Pediatrics
2005;48(9):1004-1008
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hemangiomas are the most common benign tumors of infancy. Fifteen to 30% of these patients have multiple hemangiomas. Diffuse neonatal hemangiomatosis (DNH) is a disease that often has a fatal outcome if left untreated, and is characterized by multiple cutaneous and visceral hemangiomas. Corticosteroids are the commonly accepted first line treatment, but if no effect is seen, further treatment is required such as interferon, surgical excision, embolization and radiotherapy. Interferon is effective, but the neurologic sequela including spastic diplegia can be a complication. We experienced a case of DHN in a neonate. In this case, the baby presented with multiple cutaneous and visceral hemangiomas with Kasabach-Merritt syndrome (KMS) that included thrombocytopenia and consumptive coagulophthy. The baby was successfully treated with vincristine after the failure of steroid therapy.
